Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Allergan plc (NYSE: AGN).

Full DD Report for AGN

You must become a subscriber to view this report.


Recent News from (NYSE: AGN)

Will Mullets Bail Out Allergan?
Allergan CEO Brent Saunders. Source: Business Insider I have been bearish on Allergan ( AGN ) since the second half of 2017. I thought the company's Q2 2017 revenue growth in the high single-digits was driven more by acquisitions than via organic sales. After the company reported Q1 2018 r...
Source: SeekingAlpha
Date: May, 14 2018 10:04
Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans
Analysis focus: OMER Omeros (NASDAQ: OMER ) is moving towards a rolling BLA submission for OMS721. On this good news, and despite tepid Q1 results, investors are becoming increasingly bullish the stock, as seen by its sudden 23% spike on the news of the BLA submission. OMS721 is in tri...
Source: SeekingAlpha
Date: May, 14 2018 10:00
Johnson & Johnson: Waiting On The Wave
Watching an 80-foot wave break at Nazaré, Portugal. (via YouTube ). A "Tidal Wave" Of Opioids Lawsuits Last August, the Financial times warned that a "tidal wave" of opioid-related lawsuits was headed for Johnson & Johnson ( JNJ ) and some of its competitors (paywalled here )...
Source: SeekingAlpha
Date: May, 11 2018 15:16
Trump speech on drug prices light on specifics
Key points from President Trump's speech detailing his plan to lower U.S. drug prices called American Patients First: More news on: Health Care Select Sect SPDR ETF, Vanguard Health Care ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 14:25
Allergan: Could The Break-Up Be The Solution?
Aesthetics franchise is a key franchise for Allergan ( AGN ), accounting for around $6B in sales in 2018 and still growing at low double-digit rate, thanks to a solid outlook for Botox, fillers, and breast implants. I like the company's long-term strategy and its business model, and I think ...
Source: SeekingAlpha
Date: May, 11 2018 13:30
Trump plan on drug prices to be announced this afternoon
President Trump is set to announce his plan to corral drug prices in a speech set to begin at 2:00 pm ET today. According to administration officials the plan will not include a call to Congress to allow Medicare to negotiate drug prices, a move currently prohibited under federal law. Mo...
Source: SeekingAlpha
Date: May, 11 2018 10:22
Synergy's Q1 Earnings: Slow Growth, Worrying Financials, And The Prospect Of Partnerships
On May 10th, Synergy Pharmaceuticals ( SGYP ), the long-suffering developmental-stage-turned-commercial biotech company, reported earnings for Q1 2018 and hosted an analyst call. The company posted a wafer-thin earnings beat, thanks to further progress in curbing bloated operating expenses, ...
Source: SeekingAlpha
Date: May, 11 2018 07:42
Allergan's Growth Is Really Dead
On the surface Allergan's ( AGN ) Q1 2018 results were pretty solid. The company reported revenue of $3.67 billion, up 3% Y/Y. The results were shy of the double-digit growth of the past, which I have been predicting for a while now. EBITDA of $1.6 billion was up 34% Y/Y. Management has been c...
Source: SeekingAlpha
Date: May, 11 2018 00:54
Allergan: Sell That Volatility
Allergan ( AGN ) announced first quarter earnings at the back end of April and there was nothing in the report that alerted me to a possible downswing in the current valuation. In fact, because of the restasis situation and no obvious generic competitor as of yet, management actually raised ...
Source: SeekingAlpha
Date: May, 08 2018 13:22
Allergan to Present at the Bank of America Merrill Lynch Healthcare Conference
DUBLIN , May 7, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nevada . The presentation wi...
Source: PR Newswire
Date: May, 07 2018 16:15

 


About Allergan plc (NYSE: AGN)

Logo for Allergan plc (NYSE: AGN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $52,103,907,561 - 05/11/2018
  • Issue and Outstanding: 339,063,627 - 04/27/2018

 


Recent Filings from (NYSE: AGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 16 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 09 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 06 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 23 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 13 2018
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Filing Type: 25-NSEFiling Source: edgar
Filing Date: March, 01 2018

 

 


Daily Technical Chart for (NYSE: AGN)

Daily Technical Chart for (NYSE: AGN)


Stay tuned for daily updates and more on (NYSE: AGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: AGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of AGN and does not buy, sell, or trade any shares of AGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/